Chetan Shenoy
LightNews LightNews
banner
cshenoy.bsky.social
Chetan Shenoy
@cshenoy.bsky.social
800 followers 400 following 53 posts
Cardiologist and researcher, in cardiovascular magnetic resonance imaging, at the University of Minnesota
Posts Replies Media Videos
Pinned
cshenoy.bsky.social
Chetan Shenoy @cshenoy.bsky.social · May 24
academic.oup.com/eurheartj/ad...

@escardio.bsky.social
#Cardiosky #WhyCMR #Epeeps #Medsky

Please DM me if you would like a full-text PDF of the paper!
cshenoy.bsky.social
academic.oup.com/eurheartj/ad...

#CardioSky #WhyCMR #Medsky
Response to a Letter to the Editor in Response to the Original Article "Prediction of ventricular arrhythmic outcomes in suspected cardiac sarcoidosis: a comparison of cardiovascular magnetic resonance phenotyping vs. societal recommendations for implantable cardioverter-defibrillator placement" published in the European Heart Journal. Response to a Letter to the Editor in Response to the Original Article "Prediction of ventricular arrhythmic outcomes in suspected cardiac sarcoidosis: a comparison of cardiovascular magnetic resonance phenotyping vs. societal recommendations for implantable cardioverter-defibrillator placement" published in the European Heart Journal.
October 6, 2025 at 2:17 PM
Reposted by Chetan Shenoy
hadleymd.bsky.social
Important multicenter study in #EHJ
#CMR outperforms societal recs for ICD placement in cardiac sarcoidosis
📈AUC=0.86 for 5-yr risk of fatal/life-threatening arrhythmias
⚡Highest risk = abnl LVEF + LGE that is multifocal, septal, subepicardial, or involves RV freewall
buff.ly/Nc2upbU
#cardiotwitter
September 30, 2025 at 11:02 PM
Reposted by Chetan Shenoy
kardioklick.bsky.social
Must-watch lecture on cardiomyopathy and CMR by @cshenoy.bsky.social

„more often than what is the EF we should ask the why?“

youtube.com/live/9or85hk...
Identifying the Cause of Cardiomyopathy Using CMR (Chetan Shenoy, MBBS, MS)
YouTube video by Houston Methodist DeBakey CV Education
youtube.com
July 19, 2025 at 5:40 AM
Reposted by Chetan Shenoy
tctmd.bsky.social
“CMR phenotyping can be used immediately in clinical practice to identify patients with suspected cardiac sarcoidosis who would benefit from a primary prevention ICD," said Chetan Shenoy, MD. Read more about how this can prevent life-threatening ventricular arrhythmias: www.tctmd.com/news/cmr-may...
CMR May Improve Assessment of ICD Need in Cardiac Sarcoidosis
The imaging was better than societal recommendations at discriminating long-term risk of ventricular arrhythmias.
www.tctmd.com
June 19, 2025 at 1:09 PM
cshenoy.bsky.social
Thank you, @toddneale.bsky.social, for your excellent reporting on our EHJ paper!

@tctmd.bsky.social @escardio.bsky.social @paragbawaskar.bsky.social
June 11, 2025 at 10:12 PM
Reposted by Chetan Shenoy
pabloplopez.bsky.social
#EHJCVI 🫀 What's the value of ventricular strain in systemic sclerosis? 📉 Both LVGLS and RVGLS are linked to death or MACE, unlike LVEF and RVEF 🧠 How does strain compare to traditional prognostic markers? 🔍 Read more 👉 doi.org/10.1093/ehjc... #CardioSky @jgrapsa.bsky.social @escardio.bsky.social
June 10, 2025 at 9:02 PM
cshenoy.bsky.social
Prediction of ventricular arrhythmic outcomes in suspected cardiac sarcoidosis: a comparison of cardiovascular magnetic resonance phenotyping vs. societal recommendations for implantable cardioverter-defibrillator placement

academic.oup.com/eurheartj/ad...

#Cardiosky #WhyCMR #Epeeps #Medsky
In patients with suspected cardiac sarcoidosis, CMR phenotyping showed greater discriminative accuracy than societal recommendations for predicting fatal or life-threatening ventricular arrhythmias, suggesting that it may be more effective at identifying candidates for primary prevention ICDs.
May 27, 2025 at 1:32 PM
Reposted by Chetan Shenoy
kardioklick.bsky.social
Cardiac sarcoidosis is a undervalued disease and difficult to diagnose and treat, considering potential life-threatening arrhythmias. Nice to have some more guidance.

#cardiosky.
May 25, 2025 at 7:09 AM
cshenoy.bsky.social
academic.oup.com/eurheartj/ad...

@escardio.bsky.social
#Cardiosky #WhyCMR #Epeeps #Medsky

Please DM me if you would like a full-text PDF of the paper!
May 24, 2025 at 2:39 PM
cshenoy.bsky.social
pmc.ncbi.nlm.nih.gov/articles/PMC...

#HCM #CardioSky #Cardiomyopathy
April 22, 2025 at 11:05 PM
Reposted by Chetan Shenoy
cshenoy.bsky.social
In patients with suspected cardiac sarcoidosis, cardiac FDG-PET is recommended after a normal CMR if there is a high clinical suspicion. What are the data supporting this recommendation? #CardioSky #MedSky #Sarcoidosis
March 21, 2025 at 11:39 PM
Reposted by Chetan Shenoy
mugander.bsky.social
Query sarcoid, normal #WhyCMR, so then should we do FDG-PET? Not much benefit.
cshenoy.bsky.social Chetan Shenoy @cshenoy.bsky.social · Mar 21
In patients with suspected cardiac sarcoidosis, cardiac FDG-PET is recommended after a normal CMR if there is a high clinical suspicion. What are the data supporting this recommendation? #CardioSky #MedSky #Sarcoidosis
March 23, 2025 at 5:29 AM
cshenoy.bsky.social
In patients with suspected cardiac sarcoidosis, cardiac FDG-PET is recommended after a normal CMR if there is a high clinical suspicion. What are the data supporting this recommendation? #CardioSky #MedSky #Sarcoidosis
March 21, 2025 at 11:39 PM
cshenoy.bsky.social
This paper reports the coexistence of cardiac sarcoidosis and arrhythmogenic cardiomyopathy in 5 patients.

heart.bmj.com/content/earl...

#CardioSky #MedSky
Coexistence of cardiac sarcoidosis and arrhythmogenic cardiomyopathy-associated genetic variants: a multicentre case-control study
Background Cardiac sarcoidosis (CS) is a chronic inflammatory disease characterised by non-caseating granulomas, while arrhythmogenic cardiomyopathy (ACM) is a genetic condition mainly affecting desmo...
heart.bmj.com
January 23, 2025 at 2:08 AM
cshenoy.bsky.social
Examples of study patients with serial CMR images. Patient A had resolution of LV thrombus on the first serial CMR done 64 days after the index CMR, and no recurrence was noted on subsequent serial CMRs done 688 and 1043 days after the index CMR. Patient B had no resolution of LV thrombus on serial CMRs done 591, 966, and 3555 days after the index CMR. Patient C had resolution of LV thrombus on the first serial CMR done 86 days after the index CMR; however, a new LV thrombus was identified on the second serial CMR done 401 days after the index CMR, which had resolved again by the third serial CMR done 1336 days after the index CMR.
January 5, 2025 at 6:22 PM
cshenoy.bsky.social
Short-Axis LGE Images Showing Similar Septal Midmyocardial LGE in Viral Myocarditis and Genetic Cardiomyopathy. (A) A patient with endomyocardial biopsy-proven parvovirus B19 myocarditis. Reproduced with permission from Greulich et al. (B) A patient with cardiomyopathy and likely pathogenic variants in the desmin (DES) and transforming growth factor β 3 (TGFB3) genes. (C) A patient with cardiomyopathy and a pathogenic variant in the desmoplakin (DSP) gene. (D) A patient with cardiomyopathy and a pathogenic variant in the filamin C (FLNC) gene. (E) A patient with cardiomyopathy and a pathogenic variant in the lamin A/C (LMNA) gene. (F) A patient with cardiomyopathy and a pathogenic variant in the titin (TTN) gene.
January 5, 2025 at 6:15 PM
Reposted by Chetan Shenoy
sarahhudsonuk.bsky.social
Great thread on LV thrombus and embolism risk - especially if RWMA I discuss lifelong anti coagulation with my pts even if it looks resolved on echo, good to have some data to help back this up 👇
cshenoy.bsky.social Chetan Shenoy @cshenoy.bsky.social · Nov 12
In 2019, we wrote a paper showing that patients with left ventricular thrombus have a long-term risk of embolism, extending to at least 8 years.

We were puzzled by the finding…

#CardioSky

www.ahajournals.org/doi/10.1161/...
Figure 2 from the paper. Incidence of embolism in left ventricular (LV) thrombus patients compared with matched non-LV thrombus patients. Kaplan-Meier curves demonstrate the cumulative incidence of the composite embolic end point in the LV thrombus (in red) and in the matched non-LV thrombus (in blue) groups. Note the significant difference in the cumulative incidence of embolic events between the 2 groups.
November 21, 2024 at 7:49 AM
cshenoy.bsky.social
Amazing achievement by rising star and post-doc in my lab @paragbawaskar.bsky.social, winner of the prestigious 2024 Melvin Judkins Early Career Investigator Award at #AHA24!! Congratulations!!!
@ahascience.bsky.social
November 17, 2024 at 3:46 PM
Reposted by Chetan Shenoy
load-dependent.bsky.social
It’s great that journals are coming over here, but what I have really missed after my departure from Twitter 2 years ago is this, the authors themselves presenting their works and discussing it with peers. #cardiosky #medsky #emimcc
cshenoy.bsky.social Chetan Shenoy @cshenoy.bsky.social · Nov 12
In 2019, we wrote a paper showing that patients with left ventricular thrombus have a long-term risk of embolism, extending to at least 8 years.

We were puzzled by the finding…

#CardioSky

www.ahajournals.org/doi/10.1161/...
Figure 2 from the paper. Incidence of embolism in left ventricular (LV) thrombus patients compared with matched non-LV thrombus patients. Kaplan-Meier curves demonstrate the cumulative incidence of the composite embolic end point in the LV thrombus (in red) and in the matched non-LV thrombus (in blue) groups. Note the significant difference in the cumulative incidence of embolic events between the 2 groups.
November 13, 2024 at 3:58 PM
Reposted by Chetan Shenoy
lukekc.bsky.social
With the big caveat that obvious alternative causes are not present such as AF.
November 13, 2024 at 9:03 PM
Reposted by Chetan Shenoy
lukekc.bsky.social
All patients with stroke is unrealistic in terms of cost, access and resourcing.

However in patients with ischaemic stroke, LV dysfunction and/or recent MI I agree (if #echofirst + contrast is negative for thrombus).
November 13, 2024 at 9:02 PM
Reposted by Chetan Shenoy
lukekc.bsky.social
Thanks for your insights. Fascinating area.
November 13, 2024 at 6:42 AM
Reposted by Chetan Shenoy
lukekc.bsky.social
Thanks. So for example - post anterior infarct, persisting WMA on CMR at 6 months despite OMT (but improvement in overall LVEF). Lifelong anticoagulation or would you reimage at a further interval (I.e. 12 months) to look for improvement in wall motion abnormality?
November 13, 2024 at 6:31 AM
Reposted by Chetan Shenoy
lukekc.bsky.social
Great work Chetan. An important area where as a community we need to get better at managing - particularly in the post (anterior) STEMI space. What are your thoughts on stopping anticoagulation at 3 or 6 months post MI with persisting wall motion defects but resolved thrombus?
November 13, 2024 at 6:17 AM
Reposted by Chetan Shenoy
fzores.bsky.social
Congratulations for this work! Do you have data for patients with CMR and echo to evaluate the discrepancy?

We need a well designed RCT to answer this important although infrequent question. And to assess the effectiveness of DOAC in these cases
November 13, 2024 at 6:54 AM